

IN THE CLAIMS

The status of each claim in the present application is listed below.


Please amend the claims as follows:

Claim 1 (Currently Amended): An active substance combination, comprising:  
~~characterized in that it comprises:~~

- (A) at least one compound with neuropeptide Y (NPY) -receptor affinity, and
- (B) at least one compound with 5-HT<sub>6</sub> receptor affinity,

Claim 2 (Currently Amended): The combination according to claim 1, wherein  
~~characterized in that as component (A) at least one compound with neuropeptide Y5 (NPY5)~~  
~~-receptor affinity is present.~~

Claim 3 (Currently Amended): The combination according to claim 1 or 2, wherein  
~~characterized in that as component (A) at least one compound is present, which is a selected~~  
~~from the group consisting of the 1,4-disubstituted piperidine compound compounds of~~  
~~general formula (Ia)~~



(Ia)

wherein R<sup>1a</sup>, R<sup>2a</sup>, R<sup>3a</sup>, R<sup>4a</sup> are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro, cyano, -OR<sup>12a</sup>, -O-(C=O)R<sup>13a</sup>, -(C=O)-OR<sup>13a</sup>, -SR<sup>14a</sup>, -SOR<sup>14a</sup>, -SO<sub>2</sub>R<sup>14a</sup>, -NH-SO<sub>2</sub>R<sup>14a</sup>, -SO<sub>2</sub>NH<sub>2</sub> and -NR<sup>15a</sup>R<sup>16a</sup> moiety,

$R^{5a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical,

$R^{6a}$ ,  $R^{7a}$ ,  $R^{8a}$ ,  $R^{9a}$  are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano and a  $\text{COOR}^{17a}$  moiety,

$A^a$  represents a bridge member  $-\text{CHR}^{18a}-$  or  $-\text{CHR}^{18a}\text{-CH}_2-$ ,

$B^a$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, a  $\text{COOR}^{19a}$ -moiety, a  $-(\text{C=O})\text{R}^{20a}$ -moiety, or a  $-\text{CH}_2\text{OR}^{23a}$ -moiety,

$R^{10a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{11a}$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, or an optionally at least mono substituted aryl- or heteroaryl radical, which may

be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ringsystem, or

$R^{10a}$  and  $R^{11a}$  together with the bridging nitrogen atom form an optionally at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring that may contain at least one further heteroatom as a ring member and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem,

$R^{12a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{13a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

$R^{14a}$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

$R^{15a}$  and  $R^{16a}$  each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

or  $R^{15a}$  and  $R^{16a}$  together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

$R^{17a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical,

which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{18a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{19a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{20a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or a  $NR^{21a}R^{22a}$ -moiety,


$R^{21a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{22a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at

least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{23a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, which may comprise at least one heteroatom as a chain member, or a- $(C=O)R^{13a}$ -moiety,  
optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, ~~preferably enantiomers or diastereomers~~, in any mixing ratio, or salts, ~~preferably physiologically acceptable salts thereof, or corresponding solvates.~~

Claim 4 (Currently Amended): The combination according to claim 1 or 2 any one of the claims 1 to 3, wherein characterized in that as component (B) at least one compound [[ist]] is present, which is a selected from the group consisting of the benzoxazinone-derived sulfonamide compound compounds of general formula (Ib)



(Ib)

wherein

R<sup>1b</sup>, R<sup>2b</sup>, R<sup>3b</sup>, R<sup>4b</sup> are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro, cyano, -OR<sup>10b</sup>, -O(C=O)R<sup>11b</sup>, -(C=O)OR<sup>11b</sup>, -SR<sup>12b</sup>, -SOR<sup>12b</sup>, -SO<sub>2</sub>R<sup>12b</sup>, -NH-SO<sub>2</sub>R<sup>12b</sup>, -SO<sub>2</sub>NH<sub>2</sub> and a -NR<sup>13b</sup>R<sup>14b</sup> moiety,

$R^{5b}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

$R^{6b}$ ,  $R^{7b}$ ,  $R^{8b}$ ,  $R^{9b}$  are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a  $COR^{15b}$  moiety,

$W^b$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted aryl or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene or alkenylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

a  $NR^{16b}R^{17b}$ -moiety or

a  $COR^{18b}$ -moiety,

$R^{10b}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono-

or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{11b}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

$R^{12b}$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{13b}$  and  $R^{14b}$  each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded

via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,


or R<sup>13b</sup> and R<sup>14b</sup> together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R<sup>15b</sup> represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R<sup>16b</sup> represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R<sup>17b</sup> represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and

R<sup>18</sup> represents an optionally at least mono-substituted aryl radical optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, ~~or a solvate~~, respectively, and compounds derived from sulfonamide of general formula (Ic),



wherein R<sup>1c</sup> represents hydrogen, an optionally at least mono-substituted, linear or branched alkyl radical, an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted benzyl radical,

R<sup>2c</sup> represents a -NR<sup>4c</sup>R<sup>5c</sup> moiety or a saturated or unsaturated, optionally at least mono-substituted, optionally at-least one heteroatom as ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing mono- or bicyclic cycloaliphatic ringsystem,

R<sup>3c</sup> represents hydrogen or an optionally at least mono-substituted, linear or branched alkyl radical,


R<sup>4c</sup> and R<sup>5c</sup>, identical or different, represent hydrogen or an optionally at least mono-substituted, linear or branched alkyl radical, or

R<sup>4c</sup> and R<sup>5c</sup> together with the bridging nitrogen atom form an optionally at least mono-substituted, saturated or unsaturated heterocyclic ring, which may contain at least one further heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing mono- or bicyclic cycloaliphatic ringsystem,

$A^c$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ringsystem, which may be bonded via an optionally at least mono-substituted alkylene-, an optionally at least mono-substituted alkenylene- or an optionally at least mono-substituted alkynylene group and/or may contain at least one heteroatom as a ring member in one or more of its rings,

$n_c$  represents 0,1, 2,3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt ~~or a corresponding solvate~~, and compounds of general formula (Id)



(Id)

$R^{1d}$  represents a  $-NR^{8d}R^{9d}$  radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^{2d}$ ,  $R^{3d}$ ,  $R^{5d}$ ,  $R^{6d}$  and  $R^{7d}$ , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

$R^{4d}$  is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$R^{8d}$  and  $R^{9d}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or


$R^{8d}$  and  $R^{9d}$  together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

$A^d$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and

$nd$  is 0,1, 2,3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, ~~or a corresponding solvate thereof~~, and compounds derived from sulfonamide of general formula (Ie)



wherein

wherein

$\text{R}^{1\text{e}}$  represents an  $-\text{NR}^{8\text{e}}\text{R}^{9\text{e}}$  radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

$\text{R}^{2\text{e}}$ ,  $\text{R}^{3\text{e}}$ ,  $\text{R}^{4\text{e}}$ ,  $\text{R}^{6\text{e}}$  and  $\text{R}^{7\text{e}}$ , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

$\text{R}^{5\text{e}}$  represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$\text{R}^{8\text{e}}$  and  $\text{R}^{9\text{e}}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or


R<sup>8c</sup> and R<sup>9c</sup> together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, mono- or bicyclic cycloaliphatic ring system which may optionally contain at least one heteroatom as a ring member,

A<sup>c</sup> represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and

ne is 0, 1, 2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding physiologically acceptable salt, ~~or a corresponding solvate~~, and compounds derived from sulfonamide of general formula (If)



(If)

wherein

$R^{1f}$  represents a  $-NR^{8f}R^{9f}$  radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^{2f}$ ,  $R^{3f}$ ,  $R^{4f}$ ,  $R^{5f}$  and  $R^{7f}$ , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

$R^{6f}$  represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$R^{8f}$  and  $R^{9f}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or


$R^{8f}$  and  $R^{9f}$ , together with the bridging nitrogen atom, form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one further heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$A^f$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings

and

$nf$  is 0, 1, 2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding physiologically acceptable salt, ~~or a corresponding solvate~~, and compounds derived from sulfonamide of general formula (Ig)



(Ig)

wherein

R<sup>1g</sup> is a -NR<sup>8g</sup>R<sup>9g</sup> radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring ~~system which~~ system which may optionally contain at least one heteroatom as a ring member,

R<sup>2g</sup>, R<sup>3g</sup>, R<sup>4g</sup>, R<sup>5g</sup> and R<sup>6g</sup>, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

$R^{7g}$  represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$R^{8g}$  and  $R^{9g}$ , identical or different, represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,


or

$R^{8g}$  and  $R^{9g}$  together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

$A^g$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

ng is 0,1, 2,3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding physiologically acceptable salt, ~~or a corresponding solvate~~ and compounds derived from sulfonamide of general formula (Ih)



(Ih)

wherein

$\text{R}^{1h}$  represents a  $-\text{NR}^{7h}\text{R}^{8h}$  radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$\text{R}^{2h}$ ,  $\text{R}^{3h}$ ,  $\text{R}^{4h}$ ,  $\text{R}^{5h}$  and  $\text{R}^{6h}$ , identical or different, each represent hydrogen, halogen, cyano, nitro, a linear or branched alkyl radical, a linear or branched alkenyl radical, a linear or branched alkenyl radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a cycloalkyl radical, a cycloalkenyl radical, an alkylcarbonyl radical, a phenylcarbonyl or a  $-\text{NR}^{9h}\text{R}^{10h}$  group,

$\text{R}^{7h}$  and  $\text{R}^{8h}$ , identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical,

or

$\text{R}^{7h}$  and  $\text{R}^{8h}$ , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring

member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^{9h}$  and  $R^{10h}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

$R^{9h}$  and  $R^{10h}$ , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$A^h$  and  $B^h$ , identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical

or

$A^h$  and  $B^h$ , together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

and

$nh$  is 0, 1, 2, 3 or 4

optionally in the form of one of their stereoisomers, ~~preferably enantiomers or diastereomers~~, their racemate or in the form of a mixture of at least two of their stereoisomers, ~~preferably enantiomers or diastereomers~~, at any mixture ratio, or a corresponding physiologically acceptable salt ~~or a corresponding solvate~~.

Claim 5 (Currently Amended): The combination according to claim 1 or 2 ~~any one of the claims 1 to 4, wherein characterized in that~~ it comprises 1-99% by weight of component

(A) and 99-1 % by weight of component (B),~~more preferably 10-80% by weight of component (A) and 90-20% by weight of component (B)~~, in each case referring to the total weight of both components (A) and (B).

Claim 6 (Currently Amended): A pharmaceutical composition medicament comprising an active substance combination ~~according~~ according to claim 1 or 2 any one of the claims 1 to 5 and optionally one or more pharmacologically acceptable adjuvants.

Claim 7 (Currently Amended): A pharmaceutical composition medicament according to claim 6, for simultaneous neuropeptide Y- and Y<sub>2</sub>-and 5-HT<sub>6</sub>-receptor regulation, for regulation of appetite, for maintenance, increase or reduction of body weight, for prophylaxis and/or treatment of disorders related to food ingestion, preferably for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes (non-insulin-dependent diabetes mellitus), or for prophylaxis and/or treatment of gastrointestinal tract disorders, preferably of the irritable bowel syndrome, for prophylaxis and/or treatment of Peripheral Nervous System Disorders, Central Nervous System Disorders, arthritis, epilepsy, anxiety, panic, depression, cognitive disorders, memory disorders, cardiovascular diseases, senile dementia processes, such as Alzheimer's, Parkinson's and/or Huntington's Disease, schizophrenia, psychosis, infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome, inflammatory diseases, immunologic diseases or for improvement of cognition.

Claims 8-33: (Canceled).

Claim 34 (Currently Amended): A pharmaceutical formulation, which characterized ~~in that~~ it comprises an active substance combination according to any one of claims 1 or 2 [[5]] and optionally one or more pharmacologically acceptable adjuvants.

Claim 35 (Currently Amended): The pharmaceutical formulation according to claim 34, which characterized in that it is present in solid pharmaceutical forms such as tablets, tablets, chewing tablets, chewing gums, dragees, capsules, suppositories, powder preparations, transdermal therapeutic systems, transmucosal therapeutic systems, or in liquid and semi-liquid pharmaceutical forms such as drops or such as juice, ~~syrup~~ syrup, solution, emulsion, suspension, preferably in form of tablets, capsules, drops or solution.

Claim 36 (Currently Amended): The pharmaceutical formulation according to claim 34, which characterized in that it is present in form of [[of]] multiple particles, preferably microtablets, microcapsules, microspheroids, granules, crystals or pellets, optionally compacted in a tablet, filled in a capsule or suspended in a suitable liquid.

Claim 37 (Currently Amended): The pharmaceutical formulation according to one or more of claims 34-36, which characterized in that it is for oral, intravenous, intramuscular, subcutaneous, intrathecal, epidural, buccal, sublingual, pulmonal, rectal, transdermal, nasal or intracerebroventricular application, ~~preferably oral or intravenous~~.

Claim 38 (Currently Amended): The pharmaceutical formulation according to one or more of claims 34-36, wherein characterized in that at least one of the components of the active substance combination (A) or (B) is present at least partially in sustained-release form.

Claim 39 (Currently Amended): The pharmaceutical formulation according to claim 38, wherein characterized in that the medicament has at least one coating or at least one matrix comprising at least one material, which sustains active substance release.

Claim 40 (Currently Amended): The pharmaceutical formulation according to claim 39, wherein characterized in that the sustained-release material is based on optionally modified, water-insoluble, natural, semisynthetic or synthetic polymer, or a natural wax or fat or fatty alcohol or semisynthetic or synthetic fatty acid, or on a mixture of at least two of these afore mentioned components.

Claim 41 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein characterized in that the water-insoluble polymer is based on an acrylic resin, which is preferably selected from the group of poly(meth)acrylates, poly(C<sub>1</sub>-4)dialkylamino(C<sub>1-4</sub>)alkyl (meth)acrylates and/or copolymers thereof or a mixture of at least two of the afore-mentioned polymers.

Claim 42 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein characterized in that the water-insoluble polymers are cellulose derivatives, preferably alkyl cellulose and even more preferably ethyl cellulose, or cellulose esters.

Claim 43 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein characterized in that the wax is carnauba wax, beeswax, glycerol monostearate, glycerol monobehenate, glycerol ditripalmitostearate, microcrystalline wax or a mixture of at least two of these components.

Claim 44 (Currently Amended): The pharmaceutical formulation according to one or more of claims 40-43, ~~wherein characterized in that~~ polymers have been used in combination with one or more plasticizers.

Claim 45 (Currently Amended): The pharmaceutical formulation according to one or more of claims 38-44, ~~wherein characterized in that~~ besides the sustained-release form, at least one of the active substance components (A) or (B) is present in a non-sustained-release form.

Claim 46 (New): A method of simultaneously regulating neuropeptide Y5- and 5-HT<sub>6</sub>-receptor, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 47 (New): A method of regulating appetite, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 48 (New): A method of maintaining, increasing or reducing body weight, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 49 (New): A method for prophylaxis and/or treatment of disorders related to food ingestion, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 50 (New): A method for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 51 (New): A method for prophylaxis and/or treatment of gastrointestinal tract disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 52 (New): A method for prophylaxis and/or treatment of the irritable bowel syndrome, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 53 (New): A method for prophylaxis and/or treatment of Peripheral Nervous System Disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 54 (New): A method for prophylaxis and/or treatment of Central Nervous System Disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 55 (New): A method for prophylaxis and/or treatment arthritis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 56 (New): A method for prophylaxis and/or treatment of epilepsy, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 57 (New): A method for prophylaxis and/or treatment of anxiety, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 58 (New): A method for prophylaxis and/or treatment of panic, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 59 (New): A method for prophylaxis and/or treatment of depression comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 60 (New): A method for prophylaxis and/or treatment of bipolar disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 61 (New): A method for prophylaxis and/or treatment of cognitive disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 62 (New): A method for prophylaxis and/or treatment of memory disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 63 (New): A method for prophylaxis and/or treatment of cardiovascular diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 64 (New): A method for prophylaxis and/or treatment of senile dementia processes, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 65 (New): A method for prophylaxis and/or treatment of neurodegenerative disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 66 (New): A method for prophylaxis and/or treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 67 (New): A method for prophylaxis and/or treatment of schizophrenia, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 68 (New): A method for prophylaxis and/or treatment of psychosis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 69 (New): A method for prophylaxis and/or treatment of infantile hyperkinesia or attention deficit/hyperactivity disorder, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 70 (New): A method for prophylaxis and/or treatment of pain, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 71 (New): A method for prophylaxis and/or treatment of hypertensive syndrome, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 72 (New): A method for prophylaxis and/or treatment of inflammatory diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 73 (New): A method for prophylaxis and/or treatment of immunologic diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Application No. 10/566,402  
Reply to Office Action of March 29, 2010

Claim 74 (New): A method for improving cognition, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.